GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alexza Pharmaceuticals Inc (OTCPK:ALXA) » Definitions » Gross Property, Plant and Equipment

Alexza Pharmaceuticals (Alexza Pharmaceuticals) Gross Property, Plant and Equipment : $2.75 Mil (As of Mar. 2016)


View and export this data going back to 2006. Start your Free Trial

What is Alexza Pharmaceuticals Gross Property, Plant and Equipment?

Alexza Pharmaceuticals's quarterly gross PPE increased from Sep. 2015 ($10.30 Mil) to Dec. 2015 ($25.93 Mil) but then declined from Dec. 2015 ($25.93 Mil) to Mar. 2016 ($2.75 Mil).

Alexza Pharmaceuticals's annual gross PPE increased from Dec. 2013 ($43.96 Mil) to Dec. 2014 ($45.99 Mil) but then declined from Dec. 2014 ($45.99 Mil) to Dec. 2015 ($25.93 Mil).


Alexza Pharmaceuticals Gross Property, Plant and Equipment Historical Data

The historical data trend for Alexza Pharmaceuticals's Gross Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexza Pharmaceuticals Gross Property, Plant and Equipment Chart

Alexza Pharmaceuticals Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Gross Property, Plant and Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.08 42.40 43.96 45.99 25.93

Alexza Pharmaceuticals Quarterly Data
Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
Gross Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.69 11.01 10.30 25.93 2.75

Alexza Pharmaceuticals Gross Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the company. Fixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Alexza Pharmaceuticals  (OTCPK:ALXA) Gross Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Alexza Pharmaceuticals Gross Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Alexza Pharmaceuticals's Gross Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Alexza Pharmaceuticals (Alexza Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Alexza Pharmaceuticals Inc was incorporated in the state of Delaware on December 19, 2000 as FaxMed, Inc. In June 2001, it changed the name to Alexza Corporation and in December 2001 it became Alexza Molecular Delivery Corporation. In July 2005, it changed the name to Alexza Pharmaceuticals, Inc. It is a pharmaceutical company, engaged in the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. ADASUVE is its only approved product & there is one product candidate in active development, AZ-002 (Staccato alprazolam), which is being developed for the treatment of acute repetitive seizures, sometimes called cluster seizures or ARS. ADASUVE, or Staccato loxapine, and its product candidates are based on its proprietary technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Because of the particle size of the aerosol, the drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous, or IV, administration but with greater ease, patient comfort and convenience. The pharmaceutical and biotechnology industries are intensely competitive. Many pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations are actively engaged in research and development of products targeting the same markets as ADASUVE and its other product candidates. The names "Alexza Pharmaceuticals," "Alexza," "Staccato" and "ADASUVE" are trademarks of the Company. It helds 195 issued and allowed U.S. and international patents. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of the Company's product candidates are subject to extensive regulation by governmental authorities in the United States and other countries.
Executives
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Gordon Ringold director 325 EAST MIDDLEFIELD AVENUE, MOUNTAIN VIEW CA 94043
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Thomas Braxton King director, officer: President & CEO 91 JAMES AVENUE, ATHERTON CA 94027
Joseph L Turner director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Mark K Oki officer: Former SVP, CFO, Secretary C/O ALEXZA PHARMACEUTICALS INC, 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Robert A Lippe officer: EVP, Operations & COO C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
James V Cassella director, officer: Former EVP, R&D and CSO 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Samuel D Colella other: Former Director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Alan D Frazier director
Symphony Capital Gp, L.p. 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Harri V Taranto 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Symphony Gp, Llc 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Symphony Capital Partners Lp 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, NEW YORK NY 10022
Mark Kessel 10 percent owner, other: See Footnote 2 and Remarks 950 PARK AVE APT. 11A, NEW YORK NY 10028

Alexza Pharmaceuticals (Alexza Pharmaceuticals) Headlines